Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Clinical pharmacology and therapy

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.1993.150PMID 8375124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis

  2009cited by this paper
• Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim

  1991cited by this paper
• Decreased Renal Clearance of Sodium in Cystic Fibrosis

  1991cited by this paper
• Disposition of drugs in cystic fibrosis. III. Acetaminophen

  1991cited by this paper
• Immunocytochemical localization of the cystic fibrosis gene product CFTR.

  1991cited by this paper
• Generation of cAMP-activated chloride currents by expression of CFTR.

  1991cited by this paper
• Disposition of drugs in cystic fibrosis. II. Hepatic blood flow

  1991cited by this paper
• Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study

  1990cited by this paper
• Cystic fibrosis: a disease in electrolyte transport

  1990cited by this paper
• Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

  1989cited by this paper
• Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA

  1989cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis

  1989cited by this paper
• The tubular excretion of benzylpenicillin in patients with cystic fibrosis.

  1989cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis.

  1989cited by this paper
• Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease

  1988cited by this paper
• Luminal and peritubular steps in renal transport of p-aminohippurate.

  1987cited by this paper
• Renal Function in Cystic Fibrosis

  1986cited by this paper
• Comparative pharmacokinetics of low- and high-dose ticarcillin

  1986cited by this paper
• Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis.

  1985cited by this paper
• Cloxacillin absorption and disposition in cystic fibrosis.

  1984cited by this paper
• Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.

  1984cited by this paper
• RENAL FUNCTION IN CYSTIC FIBROSIS WITH SPECIAL REFERENCE TO THE RENAL SODIUM HANDLING

  1982cited by this paper
• RENAL FUNCTION IN CYSTIC FIBROSIS

  1980cited by this paper
• Pharmacokinetics of methicillin in patients with cystic fibrosis.

  1977cited by this paper
• A new method for the determination of inulin in plasma and urine.

  1956cited by this paper

• Altered intravenous drug disposition in people living with cystic fibrosis: A meta‐analysis integrating top‐down and bottom‐up data

  2022cites this paper
• Impact of trimethoprim on serum creatinine, sodium, and potassium concentrations in patients taking trimethoprim‐sulfamethoxazole without changes in glomerular filtration rate

  2022cites this paper
• Available Evidence Indicates That Pediatric Use of Acetaminophen Adversely Affects Neurodevelopment in Susceptible Babies and Children

  2022cites this paper
• Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions

  2021cites this paper
• Satisfaction and effectiveness of opioid pain management among adults with cystic fibrosis: A mixed methods study

  2021cites this paper
• Impact of CF on the Kidneys

  2020cites this paper
• A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions

  2020cites this paper
• Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019

  2020cites this paper
• PK/PD in Critical Illness

  2020cites this paper
• Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically‐based modeling as a candle in the dark

  2020influential citation
• Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding

  2019cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Characterising the role and evolution of temperate bacteriophages in chronic respiratory infections including Cystic Fibrosis and Bronchiectasis

  2016cites this paper
• Implications of augmented renal clearance in critically ill patients

  2011cites this paper
• Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.

  2009cites this paper
• Tratamiento antimicrobiano frente a la colonización pulmonar por Pseudomonas aeruginosa en el paciente con fibrosis quística

  2009cites this paper
• Introduction to Therapeutic Drug Monitoring

  2008cites this paper
• Lack of Effect of P‐glycoprotein Inhibition on Renal Clearance of Dicloxacillin in Patients with Cystic Fibrosis

  2008cites this paper
• Activities of Cytochrome P450 1A2, N‐acetyltransferase 2, Xanthine oxidase, and Cytochrome P450 2D6 are Unaltered in Children with Cystic Fibrosis

  2004cites this paper
• Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.

  2004cites this paper
• Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis

  2004cites this paper
• Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation

  2004cites this paper
• Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis

  2003influential citation
• Lung Deposition in Cystic Fibrosis Patients Using an Ultrasonic or a Jet Nebulizer

  2003cites this paper
• Can the Enhanced Renal Clearance of Antibiotics in Cystic Fibrosis Patients Be Explained by P-Glycoprotein Transport?

  2002cites this paper
• Pharmacokinetics of High-Dose Meropenem in Adult Cystic Fibrosis Patients

  2001cites this paper
• Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine.

  2001cites this paper
• MODIFICATIONS PHARMACOCINETIQUES DANS LA MUCOVISCIDOSE

  1999cites this paper
• Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.

  1998cites this paper
• Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis.

  1998cites this paper
• Drug Disposition in Cystic Fibrosis

  1998cites this paper
• Pharmacokinetic Optimisation of Antibacterial Treatment in Patients with Cystic Fibrosis

  1998cites this paper
• Use of digitalis glycosides to identify the mechanisms of amantadine transport by renal tubules.

  1996cites this paper
• Pharmacokinetics of Antibacterials in Cystic Fibrosis

  1996cites this paper
• Assessment ofarylamine N-acetyltransfer

  1995cites this paper
• Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.

  1995cites this paper
• Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosis.

  1995cites this paper
• Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: In vitro‐in vivo correlation and characterization of its kinetics of acetylation in lymphocytes

  1994cites this paper
• Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa

  1994cites this paper
• Bicarbonate-dependent amantadine transport by rat renal cortical proximal and distal tubules.

  1994cites this paper
• Disposition of drugs in cystic fibrosis. VI. In vivo activity of cytochrome P450 isoforms involved in the metabolism of (R)‐warfarin (including P450 3A4) is not enhanced in cystic fibrosis

  1994cites this paper
• Determination of ticarcillin epimers in plasma and urine with high-performance liquid chromatography.

  1994cites this paper